...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Diffusion-weighted MRI Provides a Useful Biomarker for Evaluation of Radiotherapy Efficacy in Patients with Prostate Cancer
【24h】

Diffusion-weighted MRI Provides a Useful Biomarker for Evaluation of Radiotherapy Efficacy in Patients with Prostate Cancer

机译:扩散加权MRI提供了一种有用的生物标志物,用于评估前列腺癌患者的放射治疗疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Diffusion-weighted imaging (DWI) with measurement of apparent diffusion coefficient (ADC) allows for assessment of tumor aggressiveness. The objective of this study was to evaluate the changes of ADC value in prostate cancer after volumetric-modulated arc radiotherapy (VMAT) and to identify magnetic resonance imaging (MRI) biomarkers for monitoring tissue changes after radiotherapy. Patients and Methods: Thirty-seven patients with biopsy-proven prostate cancer treated with VMAT underwent serial MRI examinations including DWI before radiotherapy, and at 3 and 12 months after radiotherapy. ADC values of the tumor and healthy prostate tissue were measured and compared at these three time points. Results: The tumor ADC value increased significantly 3 months after radiotherapy (p<0.0001). There was a further increase of tumor ADC from 3 to 12 months after radiotherapy (p<0.01). The ADC of healthy prostate tissue did not show any significant changes. Conclusion: The ADC value is a useful biomarker for evaluating the efficacy of radiotherapy in prostate cancer.
机译:背景:具有表观扩散系数(ADC)测量的扩散加权成像(DWI)允许评估肿瘤侵袭性。本研究的目的是评估体积调制的电弧放射疗法(VMAT)后前列腺癌ADC值的变化,并鉴定磁共振成像(MRI)生物标志物,用于在放疗后监测组织变化。患者及方法:三十七名活组织检查验证前列腺癌患者用VMAT进行了序列MRI检查,包括DWI在放疗前,并在放疗后3和12个月。测量肿瘤和健康前列腺组织的ADC值并在这三个时间点进行比较。结果:放射疗法后3个月肿瘤ADC值大幅增加(P <0.0001)。放射治疗后3至12个月的肿瘤ADC进一步增加(P <0.01)。健康前列腺组织的ADC没有显示出任何重大变化。结论:ADC值是一种有用的生物标志物,用于评估放射治疗在前列腺癌中的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号